Research ArticleOriginal Research

Validation of the Male Osteoporosis Risk Estimation Score (MORES) in a Primary Care Setting

Alvah R. Cass and Angela J. Shepherd
The Journal of the American Board of Family Medicine July 2013, 26 (4) 436-444; DOI: https://doi.org/10.3122/jabfm.2013.04.120182

References

  1. 1.↵
    1. Elliott ME,
    2. Farrah RM,
    3. Binklye NC,
    4. Carnes ML,
    5. Gudmundsson A
    . Management of glucocorticoid-induced osteoporosis in male veterans. Ann Pharmacother 2000;34:1380-4.
    OpenUrlAbstract/FREE Full Text
  2. 2.↵
    1. Kiebzak GM,
    2. Beinart GA,
    3. Perser K,
    4. Ambrose CG,
    5. Siff SJ,
    6. Heggeness MH
    . Undertreatment of osteoporosis in men with hip fracture. Arch Intern Med 2002;162:2217-22.
    OpenUrlCrossRefPubMedWeb of Science
  3. 3.↵
    1. Solomon DH,
    2. Katz JN,
    3. Jacobs JP,
    4. La Tourette AM,
    5. Coblyn J
    . Management of glucocorticoid-induced osteoporosis in patients with rheumatoid arthritis. Arthritis Rheum. 2002;46:3136-42.
    OpenUrlCrossRefPubMedWeb of Science
  4. 4.↵
    1. Curtis JR,
    2. Westfall AO,
    3. Allison JJ,
    4. et al
    . Longitudinal patterns in the prevention of osteoporosis in glucocorticoid-treated patients. Arthritis Rheum 2005;52:2485-94.
    OpenUrlCrossRefPubMedWeb of Science
  5. 5.↵
    1. Feldstein AC,
    2. Nicholson GC,
    3. Orwoll E,
    4. et al
    . The near absence of osteoporosis treatment in older men with fractures. Osteoporos Int. 2005;16:953-62.
    OpenUrlCrossRefPubMedWeb of Science
  6. 6.↵
    1. Cruse LM,
    2. Valeriano J,
    3. Vasey FB,
    4. Carter JD
    . Prevalence of evaluation and treatment of glucocorticoid-induced osteoporosis in men. J Clin Rheumatol. 2006;12:221-5.
    OpenUrlCrossRefPubMedWeb of Science
  7. 7.↵
    1. Shepherd AJ,
    2. Cass AR,
    3. Ray LA,
    4. Tan A,
    5. Wilkinson GS
    . Treatment for older men with fractures. Osteoporos Int 2012;23:1041-51.
    OpenUrlCrossRefPubMed
  8. 8.↵
    1. Kanis JA,
    2. Melton LJ III.,
    3. Christiansen C,
    4. Johnston CC Jr.,
    5. Khaltaev N
    . The diagnosis of osteoporosis. J Bone Miner Res 1994;9:1137-41.
    OpenUrlPubMedWeb of Science
  9. 9.↵
    NIH Consensus Development Panel. Osteoporosis prevention, diagnosis and therapy. JAMA 2001;285:785-95.
    OpenUrlCrossRefPubMedWeb of Science
  10. 10.↵
    1. Lewis CE,
    2. Ewing SK,
    3. Taylor BC,
    4. et al
    . Predictors of non-spine fracture in elderly men: the MrOS study. J Bone Miner Res 2007;22:211-9.
    OpenUrlCrossRefPubMedWeb of Science
  11. 11.↵
    1. Melton LJ III.,
    2. Crowson CS,
    3. O'Fallon WM
    . Fracture incidence in Olmsted County, Minnesota: comparison of urban with rural rates and changes in urban rates over time. Osteoporos Int 1999;9:29-37.
    OpenUrlCrossRefPubMedWeb of Science
  12. 12.↵
    1. Day JC
    . Population projections of the United States by age, sex, and Hispanic origin: 1995 to 2050, U.S. Bureau of the Census, Current Population Reports, Washington (DC): U.S. Government Printing Office, February 1996.
  13. 13.↵
    1. Kanis JA,
    2. McCloskey E
    . Evaluation of the risk of hip fracture. Bone 1996;18:S127-32.
    OpenUrl
  14. 14.↵
    1. Forsen L,
    2. Sogaard AJ,
    3. Meyer HE,
    4. Edna T,
    5. Kopjar B
    . Survival after hip fracture: short and long-term excess mortality according to age and gender. Osteoporos Int 1999;10:73-8.
    OpenUrlCrossRefPubMedWeb of Science
  15. 15.↵
    1. Center JR,
    2. Nguyen TV,
    3. Schneider D,
    4. Sambrook PN,
    5. Eisman J
    . Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet 1999;353:878-82.
    OpenUrlCrossRefPubMedWeb of Science
  16. 16.↵
    1. Haentjens P,
    2. Magaziner J,
    3. Colón-Emeric CS,
    4. et al
    . Meta-analysis: excess mortality after hip fracture among older men and women. Ann Intern Med 2010;152:380-90.
    OpenUrlCrossRefPubMedWeb of Science
  17. 17.↵
    1. Kannegaard PN,
    2. van der mark S,
    3. Eiken P,
    4. Abrahamsen B
    . Excess mortality in men compared with women following a hip fracture: national analysis of comedications, comorbidity, and survival. Age Ageing 2010;39:203-9.
    OpenUrlAbstract/FREE Full Text
  18. 18.↵
    1. Panula J,
    2. Pihlajamäki H,
    3. Mattila VM,
    4. et al
    . Mortality and cause of death in hip fracture patients aged 65 or older: a population-based study. BMC Musculoskelet Disord 2011;12:105.
    OpenUrlCrossRefPubMed
  19. 19.↵
    1. Black DM,
    2. Cummings SR,
    3. Karpf DB,
    4. et al
    . Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 1996;347:1535-41.
    OpenUrl
  20. 20.↵
    1. Harris ST,
    2. Watts NB,
    3. Genant HK,
    4. et al
    . Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal asteoporosis: a randomized controlled trial. JAMA 1999;282:1344-52.
    OpenUrlCrossRefPubMedWeb of Science
  21. 21.↵
    1. Black DM,
    2. Thompson DE,
    3. Bauer DC,
    4. et al
    . Fracture risk reduction with alendronate in women with osteoporosis: The Fracture Intervention Trial. J Clin Endocr Metab 2000;85:4118-24.
    OpenUrlCrossRefPubMedWeb of Science
  22. 22.↵
    1. McClung MR,
    2. Geusens P,
    3. Miller PD,
    4. et al
    . Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med 2001;344:333-40.
    OpenUrlCrossRefPubMedWeb of Science
  23. 23.↵
    1. Hodsman AB,
    2. Hanley DA,
    3. Robert J
    . Do bisphosphonates reduce the risk of osteoporotic fractures? An evaluation of the evidence to date. CMAJ 2002;166:1426-30.
    OpenUrlFREE Full Text
  24. 24.↵
    1. Orwoll ES
    . Assessing bone density in men. J Bone Miner Res 2000;15:1867-70.
    OpenUrlCrossRefPubMedWeb of Science
  25. 25.↵
    1. Ho YV,
    2. Frauman AG,
    3. Thomson W,
    4. Seeman E
    . Effects of alendronate on bone density in men with primary and secondary osteoporosis. Osteoporos Int 2000;11:98-101.
    OpenUrlCrossRefPubMed
  26. 26.↵
    1. Weber TJ,
    2. Drezner MK
    . Effect of alendronate on bone mineral density in male iodiopathic osteoporosis. Metab Clin Exper 2001;50:912-5.
    OpenUrlPubMed
  27. 27.↵
    1. Gonnelli S,
    2. Cepollaro C,
    3. Montagnani AM,
    4. et al
    . Alendronate treatment in men with primary osteoporosis: a three year longitudinal study. Calcif Tissue Int 2003;73:133-9.
    OpenUrlCrossRefPubMed
  28. 28.↵
    1. Orwoll E,
    2. Ettinger M,
    3. Weiss S,
    4. et al
    . Alendronate for the treatment of osteoporosis in men. N Engl J Med 2000;343:604-10.
    OpenUrlCrossRefPubMedWeb of Science
  29. 29.↵
    1. Ringe JD,
    2. Dorst A,
    3. Faber H,
    4. Ibach K
    . Alendronate treatment of established primary osteoporosis in men: 3-year results of a prospective, comparative, two-arm study. Rheumatol Int 2004;24:110-3.
    OpenUrlCrossRefPubMedWeb of Science
  30. 30.↵
    1. Sato Y,
    2. Iwamoto J,
    3. Kanoko T,
    4. Satoh K
    . Risedronate sodium therapy for prevention of hip fracture in men 65 years or older after stroke. Arch Intern Med 2005;165:1743-8.
    OpenUrlCrossRefPubMedWeb of Science
  31. 31.↵
    1. Sawka AM,
    2. Papaioannou A,
    3. Adachi JD,
    4. Gafni A,
    5. Hanley DA,
    6. Thabane L
    . Does alendronate reduce the risk of fracture in men? A meta-analysis incorporating prior knowledge of anti-fracture efficacy in women. BMC Musculoskelet Disord. 2005;6:39.
    OpenUrlCrossRefPubMed
  32. 32.↵
    1. Sato Y,
    2. Honda Y,
    3. Iwamoto J
    . Risedronate and ergocalciferol prevent hip fracture in elderly men with Parkinson disease. Neurology 2007;68:911-5.
    OpenUrlCrossRef
  33. 33.↵
    U.S. Preventive Services Task Force. Screening for osteoporosis: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2011;154:356-64.
    OpenUrlCrossRefPubMedWeb of Science
  34. 34.↵
    1. Papaioannou A,
    2. Morin S,
    3. Cheung AM,
    4. et al
    . 2010 Clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary. CMAJ 2010;182:1864-73.
    OpenUrlFREE Full Text
  35. 35.↵
    National Osteoporosis Foundation. Physician's guide to prevention and treatment of osteoporosis. Washington, DC: National Osteoporosis Foundation; 2003.
  36. 36.↵
    1. Lim LS,
    2. Hoeksema LJ,
    3. Sherin K
    ; ACPM Prevention Practice Committee. Screening for osteoporosis in the adult U.S. population: ACPM position statement on preventive practice. Am J Prev Med 2009;36:366-75.
    OpenUrlCrossRefPubMedWeb of Science
  37. 37.↵
    1. Qaseem A,
    2. Snow V,
    3. Shekelle P,
    4. Hopkins R Jr.,
    5. Forciea MA,
    6. Owens DK
    . Screening for osteoporosis in men: a clinical practice guideline from the American College of Physicians. Ann Intern Med 2008;148:680-4.
    OpenUrlPubMedWeb of Science
  38. 38.↵
    1. Khosla S
    . Pathogenesis of age-related bone loss in humans. J Gerontol A Biol Sci Med Sci. 2012 Aug 24. [Epub ahead of print]
  39. 39.↵
    1. Koh LKH,
    2. Sedrine WB,
    3. Torralba TP,
    4. et al
    . A simple tool to identify Asian women at increased risk of osteoporosis. Osteoporos Int 2001;12:699-705.
    OpenUrlCrossRefPubMedWeb of Science
  40. 40.↵
    1. Hochberg MC,
    2. Tracy JK,
    3. van der Klift M,
    4. Pols H
    . Validation of a risk index to identify men with an increased likelihood of osteoporosis. J Bone Miner Res 2002;17(Suppl 1):S231.
    OpenUrl
  41. 41.↵
    1. Lynn HS,
    2. Woo J,
    3. Leung PC,
    4. et al
    . An evaluation of osteoporosis screening tools for the osteoporotic fractures in men (MrOS) study. Osteoporos Int 2008;19:1087-92.
    OpenUrlCrossRefPubMed
  42. 42.↵
    1. Lynn HS,
    2. Lau EMC,
    3. Wong SYS,
    4. Hong AWL
    . An osteoporosis screening tool for Chinese men. Osteoporos Int 2005;16:829-34.
    OpenUrlPubMed
  43. 43.↵
    1. Shepherd AJ,
    2. Cass AR,
    3. Carlson CA,
    4. Ray LA
    . Development and internal validation of the male osteoporosis risk estimation score. Ann Fam Med 2007;5:540-6.
    OpenUrlAbstract/FREE Full Text
  44. 44.↵
    1. Bossuyt PM,
    2. Reitsma JB,
    3. Burns DE,
    4. et al
    . Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. Fam Pract 2004;21:4-10.
    OpenUrlAbstract/FREE Full Text
  45. 45.↵
    1. Stiell IG,
    2. Wells GA
    . Methodologic standards for development of clinical decision rules in emergency medicine. Ann Emerg Med 1999;33:437-47.
    OpenUrlCrossRefPubMedWeb of Science
  46. 46.↵
    World Health Organization. WHO Scientific Group on the assessment of osteoporosis at primary health care level. Paper presented at: Summary Meeting Report, May 5-7, 2004, Brussels, Belgium.
  47. 47.↵
    1. Stone KL,
    2. Seeley DG,
    3. Lui L-Y,
    4. et al
    . BMD at multiple sites and risk of fracture of multiple types: long-term results from the study of osteoporotic fractures. J Bone Miner Res 2003;18:1947-54.
    OpenUrlCrossRefPubMedWeb of Science
  48. 48.↵
    1. Looker AC,
    2. Wahner HW,
    3. Dunn WL,
    4. et al
    . Updated data on proximal femur bone mineral levels of US adults. Osteoporos Int 1998;8:468-89.
    OpenUrlCrossRefPubMedWeb of Science
  49. 49.↵
    1. Binkley N,
    2. Bilezikian JP,
    3. Kendler DL,
    4. et al
    . Official position of the International Society for Clinical Densitometry and executive summary of the 2005 Position Development Conference. J Clin Densitometry 2006;9:4-14.
    OpenUrlCrossRefPubMedWeb of Science
  50. 50.↵
    1. Shepherd AJ,
    2. Cass AR,
    3. Carlson CA,
    4. Ray LA
    . Determining risk of vertebral osteoporosis in men: validation of the Male Osteoporosis Risk Estimation Score. J Am Board Fam Med 2010;23:186-94.
    OpenUrlAbstract/FREE Full Text
  51. 51.↵
    1. Elashoff JD
    . nQuery Advisor version 7.0. Boston: Statistical Solutions, Ltd.; 2007.
  52. 52.↵
    1. Nelson HD,
    2. Helfand M,
    3. Woolf SH,
    4. Allan J
    . Screening for postmenopausal osteoporosis: a review of the evidence for the US Preventive Services Task Force. Ann Intern Med 2002;137:529-41.
    OpenUrlPubMedWeb of Science
  53. 53.↵
    1. Kanis JA,
    2. Johnell O,
    3. Oden A,
    4. Johansson A,
    5. McCloskey E
    . FRAX and the assessment of fracture probablility in men and women from the UK. Osteoporos Int 2008;19:385-97.
    OpenUrlCrossRefPubMedWeb of Science
  54. 54.↵
    World Health Organization Collaborating Centre for Metabolic Bone Diseases. Welcome to FRAX. Available from: http://www.shef.ac.uk/FRAX/index.aspx. Accessed January 24, 2012.
  55. 55.↵
    1. Hosmer DW,
    2. Lemeshow S
    . Applied logistic regression. 2nd ed. New York: John Wiley & Sons; 2000.
  56. 56.↵
    1. Hosmer DW,
    2. Lemeshow S
    . A goodness-of-fit test for the multiple logistic regression model. Commun Stat Theory Methods 1980;9:1043-69.
    OpenUrlCrossRef
  57. 57.↵
    Wikipedia. Effects of Hurricane Ike in Texas. 2012. Available from: http://en.wikipedia.org/w/index.php?title=Effects_of_Hurricane_Ike_in_Texas. Accessed February 10, 2012.
  58. 58.↵
    1. Kanis JA,
    2. Oden A,
    3. Johnell O,
    4. Jonsson B,
    5. De Laet C,
    6. Dawson A
    . The burden of osteoporotic fractures: a method for setting intervention thresholds. Osteoporos Int 2001;12:417-27.
    OpenUrlCrossRefPubMedWeb of Science
Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools

Jump to section

Keywords